Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, LLC is a US-based company dedicated to developing innovative treatments for gastrointestinal diseases, particularly focusing on acid-related disorders that impact patient well-being. Phathom Pharmaceuticals, LLC focuses on developing treatments for gastrointestinal diseases, particularly those related to acid disorders. Founded in 2018 and headquartered in Florham Park, US, the company has raised a total of USD 150. 33 mn through various funding rounds including a Private Placement/Follow on in May 2023.

The CEO, David Socks, has a significant role in steering the company towards its goals. The firm has successfully executed 9 deals, with the most recent deal occurring on December 15, 2020. Phathom Pharmaceuticals specializes in developing innovative treatments for gastrointestinal diseases, with a strong focus on acid-related disorders. Their flagship product, VOQUEZNA® (vonoprazan), is a prescription medication designed for the treatment of Non-Erosive and Erosive Gastroesophageal Reflux Disease (GERD) in adults.

The company's therapeutic offerings aim to provide improved patient outcomes by addressing the underlying mechanisms of acid-related GI disorders. Phathom's products are marketed primarily in the United States, targeting healthcare providers and patients seeking effective management of GERD and related gastrointestinal issues, and are committed to advancing medical science through ongoing clinical programs and research initiatives. Phathom Pharmaceuticals generates revenue primarily through the commercialization of its products, particularly VOQUEZNA®. In the most recent year, the company reported a revenue of USD 682,000.

Their operations involve direct-to-consumer sales and collaborations with healthcare providers and pharmacies. Transactions typically occur through prescription fulfillment, enabling patient access to VOQUEZNA® upon medical recommendation. The company has established agreements with stakeholders in the healthcare ecosystem to maximize access to their treatments. Phathom Pharmaceuticals is focused on expanding its portfolio of therapies for acid-related diseases in North America and Europe.

The recent funding of USD 150. 33 mn raised in May 2023 will be utilized to support the clinical development and commercialization of their products, as well as for working capital and pre-commercial activities. The company aims to launch new therapies designed to enhance treatment options within the next few years, further solidifying its position in the market.